Results 21 to 30 of about 21,694,813 (356)

Alzheimer's disease drug development pipeline: 2021

Alzheimer's & Dementia, 2021
The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD.
J. Cummings, Garam Lee, K. Zhong, J. Fonseca, K. Taghva   +4 more
semanticscholar   +1 more source

The rule of five should not impede anti-parasitic drug development. [PDF]

, 2017
The "rule of 5" has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development.
Lipinski, Christopher A, McKerrow, James H   +1 more
core   +1 more source

Immuno-oncology combinations: raising the tail of the survival curve

Cancer Biology & Medicine, 2016
There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S.
Samuel J. Harris, Jessica Brown, Juanita Lopez, Timothy A. Yap   +3 more
doaj   +1 more source

Patient-centric trials for therapeutic development in precision oncology [PDF]

, 2015
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours.
A Hollebecque, A-M Tsimberidou, AD Barker, AL Tam, Andrew V. Biankin, AT Shaw, AV Biankin, B Zhang, C Le Tourneau, C Le Tourneau, C Lin, C Printz, CK Lee, CR Lindsay, D Cook, D Slamon, D Zardavas, DD Von Hoff, DE Gerber, DJ Sargent, DT Le, EA Eisenhauer, ED Green, ES Kim, F André, GD Demetri, GM Frampton, IR Watson, J Ledermann, J Lewin, J Verweij, JA Sosman, JY Douillard, L Chin, L Chin, L Seguin, LA Chantrill, LB Alexandrov, LJ Esserman, LJ Esserman, M Hay, M Maemondo, MG Kris, MR Stratton, MR Stratton, N Roper, N Waddell, NM Hylton, PA Jänne, PN Lara Jr, R Dienstmann, R Simon, RR Kalf, S Matsumoto, S Sleijfer, Simon J. Hollingsworth, SJ Dawson, SJ Mandrekar, Steven Piantadosi, TA Yap, TJ Hudson   +60 more
core   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

, 2014
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L., Goltsov, Alexey, Goltsov, Gregory, Harrison, David J., Langdon, Simon P.   +4 more
core   +5 more sources

Super-critical fluid extract of Bryonopsis laciniosa (Shivlingi) seeds restores fertility in zebrafish models through revival of cytological and anatomical features

Journal of Ovarian Research, 2022
Background The Ayurvedic system of medicine mentions the use of seeds of Bryonopsis laciniosa (L.) Naud. (also known as Shivlingi due to their unique structure resembling a ‘Shivling’) for treating sexual dysfunction, impaired fertility, and as a general
Acharya Balkrishna, Pradeep Nain, Monali Joshi, Brijesh Kumar, Anurag Varshney   +4 more
doaj   +1 more source

Current Concepts on Drug Abuse and Dependence [PDF]

, 2015
Drug addiction is a complex disease characterized by compulsive and uncontrollable desire to seek and consume the drug. In time, drug-related terminology has undergone many changes, arising from the deepening of the mechanisms of action, but also about ...
Baconi, Daniela Luiza, Bălălău, Cristian, Ciobanu, Anne-Marie, Cobani, Oana Denisa, Negrei, Carolina, Vlăsceanu, Ana Maria   +5 more
core   +3 more sources

Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease

BMC Cancer, 2021
An amendment to this paper has been published and can be accessed via the original article.
Dearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, David Dolling, Timothy Anthony Yap, Sanjay Popat, Mary E. O’Brien, Udai Banerji, Johann Sebastian de Bono, Juanita Suzanne Lopez, Nina Tunariu, Anna Minchom   +11 more
doaj   +1 more source

A brief overview of current drug repurposing approaches for COVID-19 management [PDF]

, 2020
This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares, Thomaz, Douglas Vieira   +1 more
core   +2 more sources

Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106

Pharmacology Research & Perspectives, 2023
The importance of vesicular monoamine transporter 2 (VMAT2) in dopamine regulation, which is considered crucial for neuropsychiatric disorders, is currently being studied.
Heejin Lee, Hye‐Ji Kim, Dong‐Kyu Choi, Eu n.‐A. Ko, Jae‐Hyeog Choi, Yohan Seo, Sion Lee, Soong‐Hyun Kim, Sejin Jung, Minwoo Kim, Dongwan Kang, Chun‐Young Im, Gi‐Hun Bae, Sung‐Cherl Jung, Oh‐Bin Kwon   +14 more
doaj   +1 more source